These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28801316)

  • 41. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Taylor DR; Gabrail N
    Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
    Coombes L; Burke K; Anderson AK
    Scand J Pain; 2017 Oct; 17():256-259. PubMed ID: 29229211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
    Zeppetella G
    Palliat Med; 2011 Jul; 25(5):516-24. PubMed ID: 21708858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
    Triarico S; Capozza MA; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Support Care Cancer; 2019 Oct; 27(10):3639-3645. PubMed ID: 31154533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
    Masel EK; Landthaler R; Gneist M; Watzke HH
    Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New formulations of fentanyl for acute pain management.
    Paech MJ; Bloor M; Schug SA
    Drugs Today (Barc); 2012 Feb; 48(2):119-32. PubMed ID: 22384452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
    Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
    J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
    Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse.
    Granata R; Bossi P; Bertulli R; Saita L
    Pain Med; 2014 May; 15(5):758-61. PubMed ID: 24967472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
    Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
    Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anticipatory prescribing in community end-of-life care in the UK and Ireland during the COVID-19 pandemic: online survey.
    Antunes B; Bowers B; Winterburn I; Kelly MP; Brodrick R; Pollock K; Majumder M; Spathis A; Lawrie I; George R; Ryan R; Barclay S
    BMJ Support Palliat Care; 2020 Sep; 10(3):343-349. PubMed ID: 32546559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
    Ruggeri M; Turriziani A; Oradei M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):459-64. PubMed ID: 24702061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
    Darwish M; Xie F
    Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Gombert-Handoko KB
    Clin Ther; 2014 Nov; 36(11):1704. PubMed ID: 25048312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.